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Identity 
Other names: EC 2.7.1.153; MGC142161; 
MGC14216 
PI3K; p110-alpha 







Relative size of the 21 exons of PIK3CA. The entire exon 1 is 
UTR (untranslated region). Exon numeration corresponds to the 
prevalent transcript (NM-006218). 
Description 
The PIK3CA gene spans a total genomic size of 86,190 
bases and is composed of 21 exons, 20 of them coding 
exons of varying lengths. Putative pseudogenes of 
PIK3CA have been described on chromosomes 16 (gi 
28913054) and 22q11.2  
(gi 5931525), the later one in the Cat Eye Syndrome 
region. These regions are highly homolog to the 
sequences of exons 9 and 11-13 of the PIK3CA gene. 
Transcription 
The human PIK3CA transcript has an open reading 




The PIK3CA gene encodes the p110alpha protein 
which is a catalytic subunit of the class I PI 3-kinases 
(PI3K). Class I PI3K are heterodimeric molecules 
composed of a catalytic subunit, a p110, and a 
regulatory subunit. There are three possible calatytic 




The p110alpha localizes in the cytoplasm. 
 
 
p110alpha conserved domains. Through its adaptor binding domain p110alpha interacts with the regulatory subunit. C2 domain, protein-
kinase-C-homology-2 domain. 
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Function 
Class I PI 3-kinases (PI3K) are linked to many cellular 
functions, including cell growth, prolifera-tion, 
differentiation, motility, survival and intra-celluar 
trafficking. PI3K convert PI(4,5)P2 to PI(3,4,5)P3 on 
the inner leaflet of the plasma membrane. The 
PI(3,4,)P3 provokes the recruitment to cellular 
membranes of a variety of signalling proteins, 
containing PX domain, pleckstrin homo-logy domains 
(PH domains), FYVE domains and other 
phosphoinositide-binding domains. One of these is the 
protein kinase B (PKB/AKT) a very well known 
protein that is activated as a result of its translocation to 
the cell membrane where it is then phosphorylated and 
activated by another kinase, called phosphoinositide 
dependent kinase 1 (PDK1). The phosphorylation of 
AKT leads to the activation of the TSC/mTOR 
pathway. PTEN, a tumor suppressor inactivated in 
many cancers counteracts the action of PI3K by 
dephosphoryla-ting the phosphoinositide-3,4,5-
trisphosphate (PIP3) (Lee et al., 2007).The PI3K are 
inhibited by the drugs wortmannin and LY294002 




Somatic mutations at the PIK3CA gene have been 
found in tumors and thus, it can be considered a bona 
fide oncogene (Samuels et al., 2004). Most of the 
mutations cluster in hotspots within the helical or the 
catalytic domains. 
Implicated in 
A wide variety of human cancers 
Note 
(For example, colon, breast, endometrial, ovarian, 
brain, lung, thyroid, head and neck and stomach). 
PIK3CA mutations lead to constitutive activation of 
p110alpha enzymatic activity, stimulate AKT 
signaling, and allow growth factor-independent growth 
(Bader et al., 2005). In addition, when expressed in 
normal cells, these mutations allow anchorage-
independent growth, further attesting to their important 
role in cancer development (Kang et al., 2005). 
PIK3CA somatic mutations are frequent in a variety of 
human primary tumors and cancer cell lines such as, 
among others, those of the colon, breast, and stomach 
(Samuels et al., 2004). However, in other tumors, i.e. 
those of the lung, head and neck, brain, endometrium, 
ovary, prostate, osteosarcoma and pancreas, 
hematopoietic malignancies, PIK3CA mutations are not 
as common (Angulo et al., 2008; Qiu et al., 2006; 
Muller et al., 2007; Samuels et al., 2004; Schonleben et 
al., 2006). PIK3CA gene amplifica- 
tion has also been proposed as a mechanism for 
oncogene activation in some tumors (Angulo et al., 
2008). Because PIK3CA is now considered an 
important oncogene implicated in the development of a
wide variety of human cancers, efforts are now being 
directed towards the development of mole-cules that
inhibit the activity of PI3K (Garcia-Echeverria et al., 
2008). These could be efficient in the treatment of 
those tumors carrying constitutive activation of PI3K 
pathway. PTEN is a well known tumor suppressor that
counteracts the action of PI3K by dephosphorylating 
the phosphoinositide-3,4,5-trisphosphate (PIP3). Thus, 
the treatment with drugs that inhibit p110alpha activity 
would be also potentially efficient in patients whose 
tumors carry genetic alterations at PTEN. 
It has recently been reported that activation of the PI3K 
pathway in breast tumors with concomitant ERBB2 
gene amplification, either through PIK3CA mutations 
or PTEN inactivation, underlies trastuzumab resistance. 
These findings may provide a biomarker to identify 
patients unlikely to respond to trastuzumab-based 
therapy (Berns et al., 2007). 
To be noted 
Note 
Recent evidence has shown that the PIK3CA gene is 
mutated and amplified in a range of human cancers. 
Due to that p110alpha is believed to be a promising 
drug target. A number of pharmaceutical companies ar  
currently designing and charactering potential 
p110alpha isoform specific inhibitors. 
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